Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 541 - 550 of 692 studies

Musculoskeletal

A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Than 6 Years Old

Pleural blood patch for lung ablation: a randomized trial (Oxford Pleural Embolisation Trial - OxPET) (OxPET)

Non-invasive assessment of air leak in pneumothorax using Hyperpolarised Xenon MRI (NoVANT)

Follow-up of the Long-term Outcomes of WomEn with cardiovascular conditions in pRegnancy (FLOWER)

Cancer and neoplasms

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies (SOUNDTRACK-E)

Cancer and neoplasms

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) (CHONQUER (CL3-95031-007))

A Post-Market Prospective Cohort Study on Subjects Receiving CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Surgical Procedure

Inflammatory and immune system Skin

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children from 5 to Less Than 18 Years of Age with Active Juvenile Psoriatic Arthritis (PEAPOD)

Respiratory

A randomized, double-blind, placebo-controlled, parallel-group, 52week Phase 3 trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CEREN-1)

A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib (IVO) monotherapy and azacitidine (AZA) monotherapy in adult patients with hypomethylating agent (HMA) naive myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation (PyramIDH study)